

Docket No. 249160US0X  
IN RE APPLICATION OF: Taro AOKI, et al  
SERIAL NO: 10/780,640  
FILED: February 19, 2004  
FOR: HYPERLIPEMIA THERAPEUTIC AGENT



COMMISSIONER FOR PATENTS  
ALEXANDRIA, VIRGINIA 22313

AF 2200  
Corres. and Mail  
BOX AF  
RESPONSE UNDER 37 CFR 1.116-  
EXPEDITED PROCEDURE EXAMINING  
GROUP 16/14

SIR:

Transmitted herewith is an amendment in the above-identified application.

- No additional fee is required
- Small entity status of this application under 37 C.F.R. §1.9 and §1.27 is claimed.
- Additional documents filed herewith: Executed Declaration Under 37 C.F.R. § 1.132; Goldstein et al. Principles of Drug Action, 2nd Ed, 1974, pp. 82-84, 89, 92 and 93

The Fee has been calculated as shown below:

CLAIMS	CLAIMS REMAINING		HIGHEST NUMBER PREVIOUSLY PAID	NO. EXTRA CLAIMS	RATE	CALCULATIONS
TOTAL	7	MINUS	20	0	x \$50 =	\$0.00
INDEPENDENT	3	MINUS	3	0	x \$200 =	\$0.00
		<input type="checkbox"/> MULTIPLE DEPENDENT CLAIMS			+ \$360 =	\$0.00
						TOTAL OF ABOVE CALCULATIONS
		<input type="checkbox"/> Reduction by 50% for filing by Small Entity				\$0.00
		<input type="checkbox"/> Recordation of Assignment		+ \$40 =		\$0.00
						TOTAL
						\$0.00

- A check in the amount of \$0.00 is attached.
- Credit card payment form is attached to cover the fees in the amount of \$0.00
- Please charge any additional Fees for the papers being filed herewith and for which no check or credit card payment is enclosed herewith, or credit any overpayment to deposit Account No. 15-0030. A duplicate copy of this sheet is enclosed.
- If these papers are not considered timely filed by the Patent and Trademark Office, then a petition is hereby made under 37 C.F.R. §1.136, and any additional fees required under 37 C.F.R. §1.136 for any necessary extension of time may be charged to Deposit Account No. 15-0030. A duplicate copy of this sheet is enclosed.

OBLON, SPIVAK, McCLELLAND,  
MAIER & NEUSTADT, P.C.  
Norman F. Oblon

Customer Number

22850

Tel. (703) 413-3000  
Fax. (703) 413-2220  
(OSMMN 05/03)

  
Milton Sterman  
Registration No. 27,499

DOCKET NO: 249160US0X



IN THE UNITED STATES PATENT & TRADEMARK OFFICE

IN RE APPLICATION OF

TARO AOKI, ET AL.

: EXAMINER: HENLEY III, RAYMOND J

SERIAL NO: 10/780,640

:

FILED: FEBRUARY 19, 2004

: GROUP ART UNIT: 1614

FOR: HYPERLIPEMIA THERAPEUTIC  
AGENT

:

"RESPONSE UNDER 37 CFR 1.116-  
EXPECTED PROCEDURE EXAMINING  
GROUP 1614"

AMENDMENT AFTER FINAL REJECTION

COMMISSIONER FOR PATENTS  
ALEXANDRIA, VIRGINIA 22313

SIR:

Responsive to the Final Rejection mailed April 21, 2005, please amend the subject application as follows:

**Amendments to the Specification** begin on page 2 of this paper.

**Amendments to the Claims** are reflected in the listing of claims which begins on page 3 of this paper.

**Remarks/Arguments** begin on page 5 of this paper.